JAKAVI under the microscope: new study tracks GVHD treatment in real life
NCT ID NCT07594587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in routine clinical care. The goal is to see how well JAKAVI works outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (JAKAVI)
What this could lead to
If successful, this study could confirm that ruxolitinib is a safe and effective option for managing graft-versus-host disease in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Infections are a known risk with ruxolitinib, and the study focuses on safety monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis
RECRUITINGTokyo, 105-6333, Japan